| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
68,788,000 |
| Market
Cap: |
2.17(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$14.19 - $52.31 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Arvinas is a biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies to degrade disease-causing proteins. Co. is developing ARV-110, a proteolysis targeting chimeras (PROTAC) targeted protein degrader targeting the androgen receptor protein for the treatment of men with metastatic castration-resistant prostate cancer. Co. is also developing ARV-471, a PROTAC targeted protein degrader targeting the estrogen receptor protein, or ER, for the treatment of patients with locally advanced or metastatic ER positive / HER2 negative breast cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
10,298 |
10,298 |
11,622 |
21,554 |
| Total Sell Value |
$484,521 |
$484,521 |
$516,810 |
$859,747 |
| Total People Sold |
4 |
4 |
4 |
4 |
| Total Sell Transactions |
4 |
4 |
5 |
9 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Cassidy Sean A |
Chief Financial Officer |
• – – |
2021-02-17 |
4 |
OE |
$16.00 |
$14,304 |
D/D |
894 |
155,678 |
|
- |
|
| Houston John G |
President and CEO |
• • – |
2021-02-16 |
4 |
AS |
$77.62 |
$3,466,601 |
D/D |
(44,000) |
816,200 |
|
-4% |
|
| Houston John G |
President and CEO |
• • – |
2021-02-16 |
4 |
OE |
$16.00 |
$704,000 |
D/D |
44,000 |
860,000 |
|
- |
|
| Cassidy Sean A |
Chief Financial Officer |
• – – |
2021-02-16 |
4 |
AS |
$77.60 |
$3,292,108 |
D/D |
(41,959) |
154,784 |
|
-4% |
|
| Cassidy Sean A |
Chief Financial Officer |
• – – |
2021-02-16 |
4 |
OE |
$16.00 |
$671,344 |
D/D |
41,959 |
196,743 |
|
- |
|
| Houston John G |
President and CEO |
• • – |
2021-02-16 |
4 |
OE |
$16.00 |
$24,960 |
D/D |
1,560 |
817,760 |
|
- |
|
| Peck Ronald |
Chief Medical Officer |
• – – |
2021-02-16 |
4 |
AS |
$77.35 |
$1,546,992 |
D/D |
(20,000) |
2,754 |
|
-4% |
|
| Peck Ronald |
Chief Medical Officer |
• – – |
2021-02-16 |
4 |
OE |
$26.58 |
$531,600 |
D/D |
20,000 |
22,754 |
|
- |
|
| Houston John G |
President and CEO |
• • – |
2020-12-31 |
4 |
A |
$29.02 |
$8,996 |
D/D |
310 |
818,248 |
|
- |
|
| Ratcliffe Liam |
Director |
– • – |
2020-12-18 |
4 |
B |
$70.00 |
$9,999,990 |
I/I |
142,857 |
822,857 |
2.1 |
-0% |
|
| Kennedy Edward Moore Jr. |
Director |
– • – |
2020-11-09 |
4 |
B |
$23.99 |
$199,909 |
D/D |
8,333 |
42,718 |
2.39 |
184% |
|
| Cassidy Sean A |
Chief Financial Officer |
• – – |
2020-11-09 |
4 |
OE |
$16.00 |
$48,096 |
D/D |
3,006 |
154,784 |
|
- |
|
| Canaan Partners Ix Llc |
10% Owner |
– – • |
2020-10-14 |
4 |
D |
$0.00 |
$0 |
D/D |
(400,000) |
3,589,554 |
|
- |
|
| Peck Ronald |
Chief Medical Officer |
• – – |
2020-08-14 |
4 |
S |
$27.46 |
$34,490 |
D/D |
(1,256) |
2,754 |
|
-209% |
|
| Peck Ronald |
Chief Medical Officer |
• – – |
2020-08-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,010 |
4,010 |
|
- |
|
| Canaan Partners Ix Llc |
10% Owner |
– – • |
2020-07-20 |
4 |
D |
$0.00 |
$0 |
D/D |
(500,000) |
3,989,554 |
|
- |
|
| Houston John G |
President and CEO |
• • – |
2020-06-30 |
4 |
A |
$28.50 |
$8,978 |
D/D |
315 |
817,938 |
|
- |
|
| Dixon Wendy L |
Director |
– • – |
2020-06-29 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
5,000 |
|
- |
|
| Shannon Timothy M |
Director |
– • – |
2020-06-17 |
4 |
B |
$30.26 |
$60,520 |
D/D |
2,000 |
79,546 |
2.39 |
-31% |
|
| Shannon Timothy M |
Director |
– • – |
2020-06-02 |
4 |
B |
$32.30 |
$96,900 |
D/D |
3,000 |
77,546 |
2.39 |
-19% |
|
| Ratcliffe Liam |
Director |
– • – |
2020-05-26 |
4 |
OE |
$22.06 |
$143,390 |
D/D |
6,500 |
6,500 |
|
- |
|
| Shannon Timothy M |
Director |
– • – |
2020-05-26 |
4 |
OE |
$22.06 |
$285,081 |
D/D |
12,923 |
74,546 |
|
- |
|
| Cassidy Sean A |
Chief Financial Officer |
• – – |
2020-05-13 |
4 |
OE |
$16.00 |
$21,696 |
D/D |
1,356 |
151,778 |
|
- |
|
| Cassidy Sean A |
Chief Financial Officer |
• – – |
2020-05-12 |
4 |
AS |
$60.00 |
$600,000 |
D/D |
(10,000) |
150,422 |
|
-54% |
|
| Morrison Briggs |
Director |
– • – |
2020-03-24 |
4 |
B |
$38.18 |
$95,450 |
D/D |
2,500 |
29,520 |
2.39 |
-15% |
|
174 Records found
|
|
Page 5 of 7 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.13 (0.41%) 
